RxDoctor Payments Data

Linda Spencer, MD

Dermatology · Crawfordsville, INNPI 1891794525

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 29.8% of the total. Reporting peaked in 2019 at $668 and has fallen 83.3% since, to $112 in 2024. That places this record below the midpoint for dermatology clinicians in IN, where the typical reported total is $3,818.

$2,752in general payments, 2019–2025

Across 164 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$820
  • Novartis$545
  • Lilly USA, LLC$297
  • Johnson & Johnson$240
  • Amgen$131
  • Incyte Corporation$113
  • plus $606 from 14 others
$13,330in research payments, 2019–2025

Across 14 payments — averaging $952.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$13K

What the payments were for

  • Food & beverage$2,71299%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,752 in reported general payments places this provider in the 45th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$71,614
Medicare patients
393
Services billed
1,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab27$112,224
OtezlaApremilast11$88,626
Metronidazole25$1,007
MethotrexateMethotrexate Sodium26$871
Ketoconazole31$449
Spironolactone30$273
Triamcinolone Acetonide26$220
Mupirocin13$96
Mometasone Furoate13$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$131$88,62611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 202 dermatology providers in Indiana.

Other dermatology in Crawfordsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →